Fatal capillary leak syndrome in a child with acute lymphoblastic leukemia treated with moxetumomab pasudotox for pre-transplant minimal residual disease reduction.
作者信息
Shah Nirali N, Schneiderman Jennifer, Kuruvilla Denison, Bhojwani Deepa, Fry Terry J, Martin Paul L, Schultz Kirk R, Silverman Lewis B, Whitlock James A, Wood Brent, Vainshtein Inna, Adams Alexia, Confer Dennis, Pulsipher Michael A, Chaudhury Sonali, Wayne Alan S
机构信息
Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Pediatric Hematology, Oncology and Stem Cell Transplantation, Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
出版信息
Pediatr Blood Cancer. 2021 Jan;68(1):e28574. doi: 10.1002/pbc.28574. Epub 2020 Sep 22.
Abstract
摘要
相似文献
1
Fatal capillary leak syndrome in a child with acute lymphoblastic leukemia treated with moxetumomab pasudotox for pre-transplant minimal residual disease reduction.
Pediatr Blood Cancer. 2021 Jan;68(1):e28574. doi: 10.1002/pbc.28574. Epub 2020 Sep 22.
2
Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia.
Blood. 2017 Oct 5;130(14):1620-1627. doi: 10.1182/blood-2017-02-749101. Epub 2017 Aug 9.
3
Collateral Damages by Magic Bullets: Hemolytic Uremic and Capillary Leak Syndromes After Moxetumomab Pasudotox Therapy.
Am J Med. 2019 Dec;132(12):e846-e847. doi: 10.1016/j.amjmed.2019.06.002. Epub 2019 Jun 21.
4
Results from an international phase 2 study of the anti-CD22 immunotoxin moxetumomab pasudotox in relapsed or refractory childhood B-lineage acute lymphoblastic leukemia.
Pediatr Blood Cancer. 2020 May;67(5):e28112. doi: 10.1002/pbc.28112. Epub 2020 Jan 15.
5
Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial.
J Hematol Oncol. 2021 Feb 24;14(1):35. doi: 10.1186/s13045-020-01004-y.
6
Moxetumomab Pasudotox: First Global Approval.
Drugs. 2018 Nov;78(16):1763-1767. doi: 10.1007/s40265-018-1000-9.
7
Domain II of Exotoxin Is Critical for Efficacy of Bolus Doses in a Xenograft Model of Acute Lymphoblastic Leukemia.
Toxins (Basel). 2018 May 21;10(5):210. doi: 10.3390/toxins10050210.
8
Clofarabine-induced capillary leak syndrome in a child with refractory acute lymphoblastic leukemia.
J Pediatr Hematol Oncol. 2010 Mar;32(2):144-6. doi: 10.1097/MPH.0b013e3181bf298b.
9
Moxetumomab Pasudotox: Clinical Experience in Relapsed/Refractory Hairy Cell Leukemia.
Clin J Oncol Nurs. 2019 Jun 1;23(3):E52-E59. doi: 10.1188/19.CJON.E52-E59.
10
Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse.
Leukemia. 2004 Oct;18(10):1727-8; author reply 1728-9. doi: 10.1038/sj.leu.2403475.
引用本文的文献
1
Systemic capillary leak syndrome.
Nat Rev Dis Primers. 2024 Nov 14;10(1):86. doi: 10.1038/s41572-024-00571-5.
2
How I treat refractory/relapsed hairy cell leukemia with BRAF inhibitors.
Blood. 2022 Apr 14;139(15):2294-2305. doi: 10.1182/blood.2021013502.
3
Antibody-Drug Conjugates for the Treatment of Acute Pediatric Leukemia.
J Clin Med. 2021 Aug 13;10(16):3556. doi: 10.3390/jcm10163556.
本文引用的文献
1
Results from an international phase 2 study of the anti-CD22 immunotoxin moxetumomab pasudotox in relapsed or refractory childhood B-lineage acute lymphoblastic leukemia.
Pediatr Blood Cancer. 2020 May;67(5):e28112. doi: 10.1002/pbc.28112. Epub 2020 Jan 15.
2
Reducing minimal residual disease with blinatumomab prior to HCT for pediatric patients with acute lymphoblastic leukemia.
Blood Adv. 2019 Jul 9;3(13):1926-1929. doi: 10.1182/bloodadvances.2018025726.
3
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.
Blood. 2018 Apr 5;131(14):1522-1531. doi: 10.1182/blood-2017-08-798322. Epub 2018 Jan 22.
4
Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia.
Blood. 2017 Oct 5;130(14):1620-1627. doi: 10.1182/blood-2017-02-749101. Epub 2017 Aug 9.
5
IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients.
Blood. 2015 May 28;125(22):3501-8. doi: 10.1182/blood-2014-12-615757. Epub 2015 Apr 10.
6
Current concepts in the diagnosis and management of cytokine release syndrome.
Blood. 2014 Jul 10;124(2):188-95. doi: 10.1182/blood-2014-05-552729. Epub 2014 May 29.
7
Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial.
Lancet. 2010 Dec 11;376(9757):2009-17. doi: 10.1016/S0140-6736(10)62002-8. Epub 2010 Dec 3.
8
Soluble CD22 as a tumor marker for hairy cell leukemia.
Blood. 2008 Sep 15;112(6):2272-7. doi: 10.1182/blood-2008-01-131987. Epub 2008 Jul 2.
Zotero 插件